News | October 11, 2021
Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Ectosense’s NightOwl is a leading cloud-connected home sleep apnea test
The state-of-the-art facility provides a pathway from development to large-scale biologics production
Cipla is a leading global pharma company
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
The acquisition complements and strengthens Merck’s cardiovascular pipeline
Subscribe To Our Newsletter & Stay Updated
